Table 4.
| a. PHI by RP GG. | ||
|---|---|---|
| RP pathologic GG | N (%) | PHI (median, IQR) |
| 1 (GS 6) | 1 (3.3) | 41 |
| 2 (GS 3+4=7) | 16 (53.3) | 32.9 (29.3–50.3) |
| 3 (GS 4+3=7) | 7 (23.3) | 53.3 (50.4–115.2) |
| 4–5 (GS 8-10) | 6 (20.0) | 67.6 (44.8–81.5) |
| b. PHI by RP stage. | ||
|---|---|---|
| RP pathologic stage | N (%) | PHI (median, IQR) |
| pT2N0 | 13 (43.3) | 35.5 (29.8–49.3) |
| pT3aN0 | 13 (43.3) | 50.4 (42.4–53.3) |
| pT3b/pTxN1 | 4 (13.3) | 85.0 (72.6–108.1) |
P=0.002 for GG≥3 vs. GG1-2
P=0.001 for pT3b/pTxN1 vs. ≤pT3aN0